Background: Exposure to cefotiam could cause IgE-mediated occupational allergies in hospital personnel. However, the clinically available serologic test has not been widely accepted, and the antigenic determinant of this drug is unclear. We investigated patterns of the IgE response to cefotiam in patients with occupational allergies to cefotiam. Methods: A total of 161 health care workers and 86 nonatopic healthy controls, never exposed to antibiotics, were recruited from a single tertiary hospital and the general population. A questionnaire regarding workrelated symptoms associated with cefotiam was administered. Serum specific IgE antibodies to cefotiam-human serum albumin (HSA) conjugate was measured by enzyme-linked immunosorbent assay (ELISA). Patients with work-related symptoms to cefotiam and positive specific IgE antibody to cefotiam were selected and ELISA inhibition studies were performed using sera of these patients. The inhibitors included various concentrations of free and conjugated cefotiam, ceftriaxone, ceftizoxime, and HSA alone. Results: Four patients showed work-related upper respiratory symptoms and high levels of serum specific IgE to cefotiam-HSA conjugate compared to controls. Significant inhibition patterns to free cefotiam and cefotiam-HSA conjugate were noted in patient 1 on ELISA inhibition testing, while minimal inhibitions to the other cephalosporins, both free and conjugated, were noted. In the other 3 patients, significant dose-dependent inhibitions were noted with additions of cefotiam-HSA conjugate, while minimal inhibitions were noted with free cefotiam. Among the patients, patient 2 showed minimal inhibitions with the other cephalosporins, both free and conjugated, while patient 3 and 4 showed marked dose-dependent inhibition with ceftriaxone-HSA and ceftizoxime-HSA respectively. Conclusions: The specific IgE response to cefotiam-HSA conjugate in patients with occupational allergies occurs against the hapten or new allergenic determinant in which heterogeneity of the antigenic determinant were noted depending on the individual. Background: Liver disease has been considered a prominent cause of IgE elevation. Significant differences may be observed depending on the cause of liver damage. For viral hepatitis, increased IgE concentrations have been observed during acute hepatitis A and B. Chronic hepatitis B carriers may also have high IgE levels. But no data on serum IgE levels in chronic hepatitis C and hepatitis B patients have been reported. The aim of the study was to evaluate serum IgE levels in patients with chronic hepatitis C and hepatitis B and to corelate with atopic patients. Methods: Serum IgE levels were determined in 568 adult patients with chronic hepatitis B, in 47 patients with chronic hepatitis C, and 311 patients with atopic diseases. Results: The averages of serum IgE levels were 103,9 IU/mL in chronic hepatitis C, 95,1 IU/mL in hepatits B patients, and 126,6 IU/mL in atopic patients. There was no statistically significant difference between hepatits B and hepatits C patients. Total serum IgE levels were lower in patients with either chronic hepatitis C or hepatitis B than the atopic group. Conclusions: According to the results presented, chronic hepatitis C and hepatitis B are not prominent causes of increased serum IgE values. Further studies are needed to clarify the differences and significance of IgE levels between hepatitis and atopic patients.
